Catalent, Inc. (NYSE:CTLT) Receives Average Rating of "Hold" from Brokerages

Catalent, Inc. (NYSE:CTLT - Get Free Report) has been assigned an average recommendation of "Hold" from the seven research firms that are currently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold recommendation. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $63.40.

A number of analysts have commented on the company. StockNews.com downgraded Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. William Blair reiterated a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reissued a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th.

Insider Buying and Selling at Catalent

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is owned by company insiders.

Institutional Trading of Catalent

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp lifted its stake in shares of Catalent by 1.5% in the third quarter. State Street Corp now owns 7,451,135 shares of the company's stock worth $451,315,000 after buying an additional 113,095 shares in the last quarter. Millennium Management LLC lifted its stake in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company's stock worth $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. Alpine Associates Management Inc. lifted its stake in Catalent by 3.4% in the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company's stock worth $129,082,000 after purchasing an additional 69,875 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Catalent by 14.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company's stock worth $108,559,000 after purchasing an additional 250,999 shares during the last quarter. Finally, Bank of Montreal Can grew its position in shares of Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company's stock valued at $109,388,000 after purchasing an additional 1,169,044 shares in the last quarter.

Catalent Stock Up 0.6 %

Shares of CTLT traded up $0.34 during mid-day trading on Monday, hitting $61.45. 2,090,967 shares of the company traded hands, compared to its average volume of 2,031,172. The company has a market capitalization of $11.15 billion, a PE ratio of -27.04, a price-to-earnings-growth ratio of 2.43 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The business has a 50 day moving average of $59.90 and a 200 day moving average of $58.51. Catalent has a 1-year low of $36.74 and a 1-year high of $61.50.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.10) EPS. Equities research analysts anticipate that Catalent will post 0.84 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.